Swiss National Bank
TARS icon

Swiss National Bank’s Tarsus Pharmaceuticals TARS Stock Holding History

Swiss National Bank’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.76M Sell
59,733
-3,200
-5% -$204K ﹤0.01% 1599
2026
Q1 		$4.41M Buy
62,933
+500
+0.8% +$34.9K ﹤0.01% 1434
2025
Q4 		$5.11M Buy
62,433
+1,300
+2% +$97.1K ﹤0.01% 1337
2025
Q3 		$3.63M Sell
61,133
-2,400
-4% -$118K ﹤0.01% 1504
2025
Q2 		$2.57M Buy
63,533
+8,000
+14% +$360K ﹤0.01% 1643
2025
Q1 		$2.85M Buy
55,533
+3,200
+6% +$158K ﹤0.01% 1569
2024
Q4 		$2.9M Buy
52,333
+600
+1% +$27.3K ﹤0.01% 1647
2024
Q3 		$1.7M Buy
51,733
+4,400
+9% +$124K ﹤0.01% 1957
2024
Q2 		$1.29M Buy
47,333
+4,900
+12% +$165K ﹤0.01% 2044
2024
Q1 		$1.54M Buy
42,433
+600
+1% +$17.6K ﹤0.01% 1980
2023
Q4 		$847K Sell
41,833
-7,600
-15% -$127K ﹤0.01% 2330
2023
Q3 		$878K Buy
49,433
+14,500
+42% +$257K ﹤0.01% 2311
2023
Q2 		$631K Sell
34,933
-2,500
-7% -$39.7K ﹤0.01% 2494
2023
Q1 		$471K Sell
37,433
-4,400
-11% -$64.4K ﹤0.01% 2541
2022
Q4 		$613K Buy
+41,833
New +$692K ﹤0.01% 2526

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Swiss National Bank's TARS Position: Q2 2026 in Review

Swiss National Bank reduced its Tarsus Pharmaceuticals (TARS) stake by 5.1% in Q2 2026, selling an estimated $204K and leaving 59,733 shares worth $3.76M. The position accounts for ﹤0.01% of the portfolio, ranked #1599.

Swiss National Bank first reported a position in TARS in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.11M in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Swiss National Bank held 59,733 shares of Tarsus Pharmaceuticals worth $3.76M as of Q2 2026.
  • Swiss National Bank sold 3,200 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1599 holding.
  • Swiss National Bank first reported a position in Tarsus Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Swiss National Bank's Tarsus Pharmaceuticals position peaked at $5.11M in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.